利妥昔单抗在难治性微小病变性肾病中的应用进展  

Advance in application of rituximab in refractory minimal change disease

作　　者：陈瑶 黄意雄 陈莹[1] 梁玉梅[1] Chen Yao;Huang Yixiong;Chen Ying;Liang Yumei(Department of Nephrology,Hunan People′s Hospital(The First Affiliated Hospital of Hunan Normal University),Changsha 410002,China)

机构地区：[1]湖南省人民医院(湖南师范大学附属第一医院)肾内科,长沙410002

出　　处：《中国医师杂志》2023年第5期794-797,共4页Journal of Chinese Physician

基　　金：湖南省慢性肾脏病临床医学研究中心(2019SK4009)。

摘　　要：微小病变性肾病是原发性肾病综合征的常见类型之一,目前认为B淋巴细胞与其发病关系密切。难治性微小病变性肾病患者需要糖皮质激素联合免疫抑制剂治疗。利妥昔单抗是一种消耗B细胞的单克隆抗体,用于难治性微小病变性肾病患者的治疗可降低复发率、延长缓解期、减少激素暴露,但治疗方案、不良反应应对措施尚无共识,仍需要多中心、前瞻性、大样本的研究解答。本文概述了利妥昔单抗治疗难治性微小病变性肾病的最新进展,希望为制定临床治疗策略提供帮助。Minimally degenerative nephropathy is one of the common types of primary nephrotic syndrome,and it is currently believed that B lymphocytes are closely related to its pathogenesis.Patients with refractory small degenerative kidney disease require treatment with glucocorticoids combined with immunosuppressant.Rituximab is a monoclonal antibody that consumes B cells.Its use in the treatment of patients with refractory microdegenerative kidney disease can reduce recurrence rate,prolong remission period,and reduce hormone exposure.However,there is no consensus on the treatment plan and adverse reaction response measures,and multicenter,prospective,and large-scale research answers are still needed.This article summarizes the latest progress of rituximab in the treatment of refractory minimal degenerative kidney disease,hoping to provide assistance for the development of clinical treatment strategies.

关 键 词：利妥昔单抗 微小病变性肾病 肾病综合征 

分 类 号：R692[医药卫生—泌尿科学]